Nvidia Corp. (NASDAQ: NVDA) expects fiscal second-quarter revenue of $91 billion, plus or minus 2%, matching the $91.9 billion consensus estimate. The report on Aug 26 will highlight Data Center performance and Blackwell adoption.

The company projects roughly 96.5% year-over-year growth. Data Center revenue surged 92% to $75.2 billion in the prior quarter. Management notes major hyperscalers and cloud providers have adopted the Blackwell platform.

What the Numbers Show

Nvidia’s revenue guidance of $91 billion implies a potential miss against the $91.9 billion consensus midpoint if realized at the lower end of the plus-or-minus 2% range. However, the 96.5% year-over-year growth projection underscores sustained momentum in AI infrastructure spending despite high base effects from the prior period.

ETF Exposure

Investors without direct Nvidia holdings face portfolio impact through semiconductor and technology funds. Key vehicles include:

• VanEck Semiconductor ETF (NASDAQ: SMH)
• iShares Semiconductor ETF (NASDAQ: SOXX)
• Invesco QQQ (NASDAQ: QQQ)
• Global X Robotics & Artificial Intelligence ETF (NASDAQ: BOTZ)

SMH and SOXX offer direct semiconductor exposure, while QQQ provides broader Nasdaq-100 tech access. BOTZ captures wider AI and automation trends.

Growth Drivers and Risks

Beyond GPUs, Nvidia is expanding into server CPUs with its Vera platform. The company estimates the server CPU market at roughly $200 billion and expects its CPU business to generate about $20 billion in revenue this year.

China remains a key opportunity. JPMorgan estimates every 100,000 H200 units shipped to China could generate roughly $3 billion in revenue. Conversely, rising memory costs pose margin pressure. Nvidia is reportedly considering price increases of more than 15% for some systems shipped early next year to offset these costs.

Technical Outlook

Nvidia shares trade approximately 2% above their recent average price. Volume reached 55.4 million shares on Tuesday. The stock sits within a 52-week range of $164.07 to $236.54, with resistance near $214.73. A breakout above this level could test the upper boundary of the range.

Nvidia Corp (NASDAQ: NVDA) has disclosed a stake in Generate Biomedicines Inc, signaling an expansion of its artificial intelligence ambitions beyond semiconductor hardware into the biotechnology sector.

The investment was revealed in Nvidia’s latest Form 13F filing with the US Securities and Exchange Commission. Generate Biomedicines is positioned to leverage machine learning as the core operating logic for its drug discovery platform, rather than treating AI as a supplementary tool.

From Educated Guesses to Machine-Scale Discovery

Gevorg Grigoryan, co-founder and chief technology officer of Generate Biomedicines, stated that the company was founded on the conviction that machine learning can make biology programmable. This approach aims to transform the traditional drug discovery process by shifting from scarce scientific hypotheses to abundant, machine-scale generation.

Grigoryan explained that in the age of AI, educated guesses become available at scale. To capitalize on this, Generate combines large-scale AI generation with equally large-scale experimentation. The company refers to this methodology as "intentionality at scale."

The platform rapidly generates potential drug candidates, validates them through experiments, and learns from the results. This continuous cycle allows the company to test orders of magnitude more intentional hypotheses than traditional approaches.

According to Grigoryan, this process ultimately increases the probability of clinical success while helping deliver better medicines to patients.

What the Numbers Show

Nvidia’s stake in Generate Biomedicines represents a strategic diversification into life sciences. While the specific financial value of the stake was not disclosed in the provided source, the move aligns Nvidia’s hardware capabilities with high-growth software applications in biotech. The focus on "intentionality at scale" suggests a shift from purely computational power to integrated experimental validation in drug development.